Matches in SemOpenAlex for { <https://semopenalex.org/work/W49127616> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W49127616 endingPage "480" @default.
- W49127616 startingPage "468" @default.
- W49127616 abstract "To assess the safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular (CV) events by observing the levels of blood pressure (BP) and by recording the incidence of cough in these patients, a study was conducted in a total of 1048 patients who participated in the registry. Eligible patients in this prospective, observational, longitudinal, multicentre registry included all normotensives--including treated hypertensives--with BP <140/90 mm Hg, a history of coronary aritery disease and a history of cerebrovascular disease, peripheral arterial disease or diabetes (with micro-albuminuria) or dyslipidaemia, in whom ramipril was indicated for CV risk reduction and had been prescribed by the treating physician. The primary outcome was the effect on BP at 8 weeks, and the secondary outcome was the incidence of cough at 8 weeks. Ramipril was initiated at 2.5 mg once daily (OD) for a week, followed by 5 mg OD for 3 weeks and was then increased to 10 mg OD. Data was analysed using ANOVA and Chi-square test. A total of 1,048 patients participated in this registry; 868 (82.82%) continued with the treatment till the end of the registry (ie, 8 weeks). At baseline, systolic BP was 130.10 +/- 5.38 mm Hg, while diastolic BP was 81.07 +/- 4.36 mm Hg. At 8 weeks, these values changed non-significantly to 123.41 +/- 6.33 mm Hg and 79.03 +/- 4.84 mm Hg, respectively. At week 1, 41 patients had cough, which increased non-significantly to 58 by week 8. Only 6 patients complained of severe cough at week 8, which did not lead to treatment discontinuation. Tolerability of the treatment was assessed to be 'excellent' or 'good' by 63.3% patients and 67% physicians. Treatment with ramipril 10 mg daily in patients with high risk of CV events and normal/ controlled BP produced neither a significant fall in BP nor significant adverse events in real-world clinical practice and was well tolerated." @default.
- W49127616 created "2016-06-24" @default.
- W49127616 creator A5073998287 @default.
- W49127616 date "2008-07-01" @default.
- W49127616 modified "2023-09-26" @default.
- W49127616 title "Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study." @default.
- W49127616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18975506" @default.
- W49127616 hasPublicationYear "2008" @default.
- W49127616 type Work @default.
- W49127616 sameAs 49127616 @default.
- W49127616 citedByCount "1" @default.
- W49127616 countsByYear W491276162014 @default.
- W49127616 crossrefType "journal-article" @default.
- W49127616 hasAuthorship W49127616A5073998287 @default.
- W49127616 hasConcept C120665830 @default.
- W49127616 hasConcept C121332964 @default.
- W49127616 hasConcept C126322002 @default.
- W49127616 hasConcept C134018914 @default.
- W49127616 hasConcept C141071460 @default.
- W49127616 hasConcept C197934379 @default.
- W49127616 hasConcept C23131810 @default.
- W49127616 hasConcept C2776174234 @default.
- W49127616 hasConcept C2778375690 @default.
- W49127616 hasConcept C2779888176 @default.
- W49127616 hasConcept C555293320 @default.
- W49127616 hasConcept C61511704 @default.
- W49127616 hasConcept C71924100 @default.
- W49127616 hasConcept C84393581 @default.
- W49127616 hasConceptScore W49127616C120665830 @default.
- W49127616 hasConceptScore W49127616C121332964 @default.
- W49127616 hasConceptScore W49127616C126322002 @default.
- W49127616 hasConceptScore W49127616C134018914 @default.
- W49127616 hasConceptScore W49127616C141071460 @default.
- W49127616 hasConceptScore W49127616C197934379 @default.
- W49127616 hasConceptScore W49127616C23131810 @default.
- W49127616 hasConceptScore W49127616C2776174234 @default.
- W49127616 hasConceptScore W49127616C2778375690 @default.
- W49127616 hasConceptScore W49127616C2779888176 @default.
- W49127616 hasConceptScore W49127616C555293320 @default.
- W49127616 hasConceptScore W49127616C61511704 @default.
- W49127616 hasConceptScore W49127616C71924100 @default.
- W49127616 hasConceptScore W49127616C84393581 @default.
- W49127616 hasIssue "7" @default.
- W49127616 hasLocation W491276161 @default.
- W49127616 hasLocation W491276162 @default.
- W49127616 hasOpenAccess W49127616 @default.
- W49127616 hasPrimaryLocation W491276161 @default.
- W49127616 hasRelatedWork W101678993 @default.
- W49127616 hasRelatedWork W139363841 @default.
- W49127616 hasRelatedWork W141220594 @default.
- W49127616 hasRelatedWork W1469852319 @default.
- W49127616 hasRelatedWork W1984818678 @default.
- W49127616 hasRelatedWork W1990854157 @default.
- W49127616 hasRelatedWork W2032580900 @default.
- W49127616 hasRelatedWork W2053067596 @default.
- W49127616 hasRelatedWork W2263287413 @default.
- W49127616 hasRelatedWork W2312232464 @default.
- W49127616 hasRelatedWork W2351917894 @default.
- W49127616 hasRelatedWork W2396613413 @default.
- W49127616 hasRelatedWork W2405774089 @default.
- W49127616 hasRelatedWork W2409909774 @default.
- W49127616 hasRelatedWork W2412543651 @default.
- W49127616 hasRelatedWork W2465355691 @default.
- W49127616 hasRelatedWork W2767740630 @default.
- W49127616 hasRelatedWork W328046541 @default.
- W49127616 hasRelatedWork W2624282436 @default.
- W49127616 hasRelatedWork W2935434608 @default.
- W49127616 hasVolume "106" @default.
- W49127616 isParatext "false" @default.
- W49127616 isRetracted "false" @default.
- W49127616 magId "49127616" @default.
- W49127616 workType "article" @default.